Eli Lilly drug prolongs patients' lives in lung cancer trial

02/20/2014 | Reuters

A late-stage trial showed Eli Lilly and Co.'s experimental drug ramucirumab, in combination with docetaxel, significantly improved survival and progression-free survival in patients with non-small cell lung cancer compared with a combination of placebo and docetaxel. Eli Lilly plans to submit the drug for regulatory review for this indication later this year. Ramucirumab is also under development for treatment of liver cancer and colorectal cancer.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX